Carboplatin-based chemotherapy in patients with gynecological malignancies on long-term hemodialysis

Anticancer Drugs. 2003 Oct;14(9):735-8. doi: 10.1097/00001813-200310000-00008.

Abstract

We report on three cases of long-term dialysis patients with gynecological malignancies who were successfully treated with chemotherapy. Two epithelial ovarian carcinoma patients were treated with a single agent, carboplatin (100-200 mg/m2). One recurrent endometrial carcinoma patient was treated with carboplatin (200 mg/m2) and paclitaxel (135 mg/m2). Hemodialysis was started 2 h after the carboplatin infusion and lasted 4 h in all three cases. All patients tolerated these therapies without significant myelosuppression or severe side-effects. Our findings suggest these regimens are feasible, and the combination of paclitaxel and carboplatin is effective chemotherapy when administered to long-term hemodialysis patients with recurrent endometrial carcinoma.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carboplatin / administration & dosage
  • Carboplatin / therapeutic use*
  • Endometrial Neoplasms / complications
  • Endometrial Neoplasms / drug therapy
  • Female
  • Genital Neoplasms, Female / complications*
  • Genital Neoplasms, Female / drug therapy*
  • Humans
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Ovarian Neoplasms / complications
  • Ovarian Neoplasms / drug therapy
  • Paclitaxel / administration & dosage
  • Renal Dialysis
  • Renal Insufficiency / complications
  • Renal Insufficiency / therapy*
  • Time Factors

Substances

  • Antineoplastic Agents
  • Carboplatin
  • Paclitaxel